# QGL: Transcutaneous Nerve Stimulator For Adhd

- Device class: 2; regulation: 21 CFR 882.5898; FDA's rule: 510(k) required
- FDA decisions: 5
- 510(k) review time 2021–2025: median 225 days (middle half 104–369)
- Recalls: 0 (0 Class I)
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026; MAUDE to Sep 30, 2026

## Decisions per year (last 10)
- 2019: 1
- 2023: 1
- 2024: 2
- 2025: 1

## Most-cited predicates
- DEN180041: Monarch eTNS System (2019), cited by 3
- K213629: SMILE (2023), cited by 1

Source page: https://510kreport.com/product-code/QGL
Data by year (CSV): https://510kreport.com/product-code/QGL.csv